Kennedy Capital Management LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 16,526 shares of the company's stock, valued at approximately $1,353,000.
A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after purchasing an additional 521,204 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Vaxcyte by 3.0% during the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock worth $234,884,000 after buying an additional 82,997 shares in the last quarter. Geode Capital Management LLC grew its position in Vaxcyte by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock worth $229,495,000 after buying an additional 102,106 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Vaxcyte by 8.1% in the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock valued at $145,659,000 after buying an additional 133,448 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Vaxcyte by 3.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,341,773 shares of the company's stock valued at $109,838,000 after acquiring an additional 45,936 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.
Vaxcyte Stock Up 5.3 %
Shares of Vaxcyte stock traded up $1.53 on Friday, hitting $30.65. 1,724,222 shares of the company traded hands, compared to its average volume of 1,218,023. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The company has a 50-day moving average price of $61.81 and a 200 day moving average price of $83.64. The company has a market cap of $3.95 billion, a PE ratio of -6.66 and a beta of 1.26.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on PCVX. Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group decreased their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $136.50.
Check Out Our Latest Report on PCVX
Insider Buying and Selling at Vaxcyte
In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 32,000 shares of company stock worth $2,638,800 over the last ninety days. 3.10% of the stock is currently owned by insiders.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
